



Ocrelizumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Ocrelizumab
ATC codes	L04AA36
Medicine type	Biological agent
EML status history	Application rejected in 2019 (TRS 1021) for Relapsing-remitting multiple sclerosis Application rejected in 2023 (TRS 1049) for Multiple sclerosis
Wikipedia	Ocrelizumab 
DrugBank	Ocrelizumab 

Recommendations

Section Medicines for multiple sclerosis

Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

